MRI-Ultrasound Fusion-Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over-Detection through Improved Risk Stratification

MRI-ultrasound fusion-targeted prostate biopsy (MRF-TB) may improve detection of prostate cancer (PCa) in men presenting for prostate biopsy. We report clinical outcomes of 12-core systematic biopsy (SB) and MRF-TB in men presenting for primary biopsy and further describe pathological characteristics of cancers detected by SB and not by MRF-TB.

Clinical outcomes of 435 consecutive men who underwent pre-biopsy mpMRI followed by MRF-TB and SB at our institution between June 2012 and March 2015 were captured in an IRB-approved database Clinical characteristics, biopsy results and MRI suspicion scores (mSS) were queried from the database.

Among 370 men (mean age 64±8. 5 years; mean PSA 6. 8, SEM 0. 3 ng/mL) who met inclusion criteria, PCa was detected in 200 (54. 1%) cases. Cancer detection rates for SB and MRF-TB were 47. 3% and 43. 5%, respectively (p = 0. 104). MRF-TB detected more Gleason score ≥7 cancers than SB (114/128 (89. 1%) vs 95/128 (74. 2%), respectively, p = 0. 008). Of 39 cancers detected by SB, but not by MRF-TB, 32/39 (82. 1%) demonstrated Gleason 6 disease, and 24/39 (61. 5%) and 32/39 (82. 1%) were clinically insignificant by Epstein and UCSF CAPRA (score ≤ 2) criteria, respectively.

In men presenting for primary prostate biopsy, MRF-TB detects more high grade cancers than SB. Most cancers detected by SB, and not by MRF-TB, are clinically low-risk. Pre-biopsy MRI followed by MRF-TB reduces detection of low-risk cancers while significantly improving detection and risk-stratification of high-grade disease.

The Journal of urology. 2015 Jun 19 [Epub ahead of print]

Neil Mendhiratta, Andrew B Rosenkrantz, Xiaosong Meng, James S Wysock, Michael Fenstermaker, Richard Huang, Fang Ming Deng, Jonathan Melamed, Ming Zhou, William C Huang, Herbert Lepor, Samir S Taneja

School of Medicine, NYU Langone Medical Center, New York, NY. , Department of Radiology, NYU Langone Medical Center, New York, NY. , Department of Surgery, NYU Langone Medical Center, New York, NY. , Department of Urology, New York Hospital Queens, Flushing, NY. , School of Medicine, NYU Langone Medical Center, New York, NY. , Department of Urology, NYU Langone Medical Center, New York, NY. , Department of Pathology, NYU Langone Medical Center, New York, NY. , Department of Pathology, NYU Langone Medical Center, New York, NY. , Department of Pathology, NYU Langone Medical Center, New York, NY. , Department of Urology, NYU Langone Medical Center, New York, NY. , Department of Urology, NYU Langone Medical Center, New York, NY. , Department of Urology, Department of Radiology, NYU Langone Medical Center, New York, NY. Electronic address: samir. taneja@nyumc. org.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe